

Award Number: DAMD17-00-1-0164

TITLE: Characterization of S-phase Specific BRCA1-containing
Complex

PRINCIPAL INVESTIGATOR: Fanglei You, M.D., Ph.D.
Jeffrey D. Parvin, M.D., Ph.D.

CONTRACTING ORGANIZATION: Brigham and Women's Hospital
Boston, Massachusetts 02115

REPORT DATE: June 2003

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030904 054

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2003	3. REPORT TYPE AND DATES COVERED Annual Summary (1 Jun 00 - 30 May 03)	
4. TITLE AND SUBTITLE Characterization of S-phase Specific BRCA1-containing Complex			5. FUNDING NUMBERS DAMD17-00-1-0164	
6. AUTHOR(S) Fanglei You, M.D., Ph.D. Jeffrey D. Parvin, M.D., Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Brigham and Women's Hospital Boston, Massachusetts 02115 E-Mail: jparvin@rics.bwh.harvard.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) This study will fully characterize the function of a BRCA1-containing protein complex, which appears in cells following DNA replication arrest using hydroxyurea. The complex, originally referred to as the S-phase specific complex and now termed the Hydroxyurea Induced Complex (HUIC), was observed in HeLa and in 293 cells. Hydroxyurea treatment of cells results in the reduction of BRCA1 content in the RNA polymerase II holoenzyme complex with a complementary increase in the HUIC. We have begun to characterize both complexes, and we find that the HUIC does not contain the repair proteins RAD50/MRE11/NBS1 as originally surmised, but does contain BRCA1 and the BARD1 polypeptides. We model that the HUIC results from the proteolytic degradation of the RNA polymerase II holoenzyme following DNA damage. Work is continuing to identify the polypeptides which compose the HUIC and to determine its role in breast cancer.				
14. SUBJECT TERMS BRCA1, S-phase, RNA polymerase II			15. NUMBER OF PAGES 13	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	4
References.....	5
Reportable Outcomes.....	6
Conclusions.....	6
Appendices.....	6

Annual Summary Report

Award Number DAMD17-00-1-0164

PI: Fanglei You, MD, PhD

Introduction

In this past year the PI for this project was changed from Natsuko Chiba, MD, PhD, to Fanglei You, MD, PhD. The goals of this project are unchanged.

This project will identify key functions of the breast and ovarian specific tumor suppressor protein, BRCA1. We have developed a series of BRCA1 deletion mutants for studying the S-phase specific protein complex, which we have named the HydroxyUrea Induced Complex (HUIC). While we were using these deletion mutants to facilitate the purification of the HUIC and the RNA polymerase II holoenzyme, both of which contain BRCA1, we found that expression of one of these deletion mutants powerfully suppressed the growth of breast cells in tissue culture. Since BRCA1 mutations are specifically associated with breast cancer, understanding this dominant growth suppressive phenotype of the BRCA1 mutant in breast cells became a priority. Task 3 was modified to accommodate this important new direction. Characterization of the HUIC biochemical activities (the original tasks 3 and 4) have turned out to be quite large and complicated aims, and these tasks are currently being pursued by several individuals in the lab, along with Dr. You.

Body and key research outcomes

Tasks 1 and 2. Compare polypeptides in holoenzyme vs HUIC and clone the genes encoding these polypeptides.

In work already described in past reports, we have expressed epitope-tagged BRCA1, partially purified the protein complexes containing the tagged BRCA1, and we have compared the polypeptide compositions. Specifically, we have shown that BARD1 is a component of the HUIC, and we have no evidence for other components. The data are consistent with a model that the BRCA1 ubiquitination activity degrades the RNA polymerase II holoenzyme complex, leaving a residual complex containing BRCA1 and BARD1, and we call this residual complex the HUIC (Chiba and Parvin, 2001; Chiba and Parvin, 2002; Parvin, 2001). In the original application, it had been hypothesized that the HUIC was similar to the RAD50/MRE11/NBS1 complex associated with BRCA1, but our data clearly demonstrate that this is not the case (Chiba and Parvin, 2001).

Tasks 3. Characterization of the growth suppressive activity of BRCA1 amino terminal deletion mutant.

We have found that among the various deletion mutants of BRCA1 generated in Task 1, that deletion of the amino-terminal 300 amino acid residues results in a protein that suppresses the growth of the breast cell line, MCF10A. We find that the other deletion mutants we have generated do not suppress the growth. Important for this project, this deletion mutant blocks the formation of the HUIC, the complex at the focus of the experiments. This result is surprising and important since this reflects the tumor suppressive function of BRCA1. The surprising aspect of the growth suppression is that the key domain of BRCA1 for function is the amino terminus, and it is deletion of this domain that causes growth suppression. It is possible that we have deleted the enzymatic domain of BRCA1 but retained the protein-protein interaction domain, making this a dominant-negative inhibitor of BRCA1 function. We have assayed the effects of the expression of this BRCA1 deletion mutant in non-breast cell lines, and we find that among the cell lines tested, the effect is breast specific. From other work in the lab, we have noted that some of the effects of BRCA1 inhibition result in amplification in the number of centrosomes. We tested this phenotype, and we find that expression of this deletion mutant causes an over-replication of centrosomes in breast cells, but not in another cell type, and the other deletion mutants and wild-type BRCA1 do not cause the centrosome amplification. Taken together, these data suggest that when we block BRCA1 function, there is a breast cell specific inhibition of growth, possibly secondary to over-replication of centrosomes. The experiments described here are nearing completion, and we are anticipating submitting them for publication within a month. (The anticipated author line will be You, Chiba, and Parvin.)

Task 4. Characterization of the biochemical activities of the HUIC.

As described above, this task turned out to be quite a large undertaking and is the subject of the experiments of two individuals, along with Dr. You. We had originally proposed that the HUIC would contain the RAD50/MRE11/NBS1 complex, and we would study the exonuclease activity of this complex in association with BRCA1. We have clearly shown that the HUIC is not this exonuclease, so those proposed experiments were unnecessary. Since we have found that the HUIC contains BRCA1 and BARD1, and we have no evidence of other subunits, we have prepared full length BRCA1 and BARD1 from recombinantly expressed genes using baculovirus-infected insect cells. We have found that these have ubiquitin-ligase activities, and we are currently identifying substrates for ubiquitination that affect the biology of the breast cell. We have also found that this HUIC complex binds to DNA with structural specificity. The HUIC binds to DNA that models the recombination intermediate called the Holliday junction.

References cited:

1. Chiba N, Parvin JD Redistribution of BRCA1 among four different protein complexes following replication blockage. *J Biol Chem* 2001; 276, 38549-38554.

2. Chiba N, Parvin JD. The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. **Cancer Research** 2002; 62, 4222-4228.
3. Parvin JD BRCA1 at a branch point. **Proc Natl Acad Sci USA** 2001; 98, 5952-4.

Reportable Outcomes: Publications resulting from DAMD17-00-1-0164:

No new manuscripts in this year. One is anticipated to be submitted in the very near future.

From previous years:

1. Chiba N, Parvin JD Redistribution of BRCA1 among four different protein complexes following replication blockage. **J Biol Chem** 2001; 276, 38549-38554.
2. Chiba N, Parvin JD. The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. **Cancer Research** 2002; 62, 4222-4228.

Conclusions

We have characterized the BRCA1-containing protein complex, the HUIC. This protein complex is found during the S-phase of the cell cycle and following hydroxyurea treatment. It is likely that either the formation or the function of this complex is critical to the tumor suppression activity of BRCA1. Along with BRCA1, this complex contains the BARD1 protein, but it does not contain the repair proteins, such as RAD51/MRE11/NBS1 or Ku70/80. Expression of a deletion mutant of BRCA1, which blocks formation of the HUIC, results in a growth inhibition in breast cells and in an amplification of centrosome number. These results implicate the HUIC in regulating cell growth and centrosome replication. The experiments supported by this fellowship have delineated the protein complexes with which BRCA1 associates in cells and the outcomes to the mammary cell when the formation of these protein complexes is blocked.

Appendix

See enclosed papers from this work. One reprint of Chiba and Parvin, 2002, is included. The anticipated manuscript of You, Chiba, and Parvin is not yet ready to be sent.

The BRCA1 and BARD1 Association with the RNA Polymerase II Holoenzyme¹

Natsuko Chiba and Jeffrey D. Parvin²

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115

ABSTRACT

We have previously shown that endogenous BRCA1 and overexpressed epitope-tagged BRCA1 are present in the transcription complex called the RNA polymerase II holoenzyme (holo-pol). In this study, we further characterized BRCA1 association with the holo-pol by overexpressing deletion mutants of epitope-tagged BRCA1. We found that BRCA1-associated RING domain protein (BARD1) is a component of the holo-pol complex. Deletion of the BRCA1 NH₂ terminus, which is bound by BARD1 as well as other proteins, eliminates >98% of BRCA1 association with the holo-pol. In contrast with earlier observations, deletion of the COOH terminus of BRCA1 did not affect significantly the association with holo-pol. Immunocytochemistry of expressed full-length and deletion mutants of BRCA1 showed that the NH₂ terminus of BRCA1 is important for nuclear dot formation in S-phase. An intact BRCA1 NH₂ terminus is required for the association with holo-pol and for subnuclear localization in S-phase foci. Taken together, these data support a role for BRCA1 regulation of holo-pol function.

INTRODUCTION

The breast and ovarian cancer susceptibility gene *BRCA1* is involved in the processes of transcription, DNA repair, and ubiquitination. How *BRCA1* mediates these diverse functions is unclear.

BRCA1 is a component of the RNA holo-pol³ (1, 2). The holo-pol contains the core RNA polymerase II enzyme plus many accessory factors. *BRCA1* fused to a DNA-binding domain activates transcription in cell-free systems to a similar extent as does the powerful activator, VP16 (3, 4). Many transcriptional regulators have been reported to interact with *BRCA1*, e.g., RNA Pol II, RNA helicase A, p53, STAT1, myc, CtIP, ZBRK1, ATF family members, and estrogen receptor (3, 5-15). The presence of *BRCA1* in the main mRNA synthesizing transcription machine, the holo-pol complex, and *BRCA1* association with regulators of transcription highlight the importance of *BRCA1* transcription function.

BARD1, the *BRCA1*-associated RING domain protein, has been identified as a protein that associates with the NH₂ terminus of *BRCA1* (16). BARD1 protein has a RING finger motif and BRCT repeat, as has *BRCA1*. After DNA damage, *BRCA1*-BARD1 association is stimulated, and the polyadenylation of mRNA transcripts is repressed (17). *BRCA1* has ubiquitin polymerase activity by itself, and the BARD1 association significantly enhances the ubiquitin polymerase activity (18-20). Specific targets of *BRCA1*-mediated ubiquitination have not been identified. The potential importance of ubiquitination in *BRCA1* function is also suggested by the association of the NH₂ terminus of *BRCA1* with a de-ubiquitinating enzyme known as *BRCA1*-associated protein 1 (BAP1; Ref. 21).

Subcellular localization of *BRCA1* changes are dynamically dependent on the cell cycle or DNA damage. In S-phase of cell cycle, *BRCA1* localizes to discrete nuclear foci (dots) with BARD1 and Rad51 (22-24). The protein complexes in the nuclear foci are unknown. It is unknown which *BRCA1* domain is important for the structure of nuclear dots and whether *BRCA1* changes of subcellular positions correlate with the holo-pol association.

In this study, we analyzed the *BRCA1* association with holo-pol using deletion mutants of *BRCA1*. We found that BARD1 is a component of the holo-pol, and deletion of the *BRCA1* NH₂ terminus severely limits the association of the mutant *BRCA1* protein with the holo-pol complex. This deletion mutant also fails to form nuclear foci, leading to the suggestion that the nuclear foci might contain holo-pol, although other protein complexes associated with the *BRCA1* NH₂ terminus may be responsible for the *BRCA1* nuclear dot formation. Our data suggest that *BRCA1* is involved in the function of Pol II in several ways via association with the holo-pol and possibly via subnuclear localization.

MATERIALS AND METHODS

Cell Culture and Biochemical Purification. 293S cells were passaged in suspension culture using standard procedures. About 5×10^9 cells were infected with recombinant adenovirus at a MOI of about 0.4-1.0 pfu/cell and cells were harvested 44 h after infection. The purification from whole cell extracts by chromatography on a Biorex70 ion exchange matrix and sucrose gradient sedimentation have been described previously (1, 2). On a Biorex70 ion exchange matrix, 600-1000 mg of whole cell extracts were fractionated. About 70% of the extract protein did not bind to the column, 5% was in the 0.3 M KOAc peak, 8% was in the 0.6 M KOAc peak, and 2% was in the 1.5 M KOAc peak. Distributions of *BRCA1* on Biorex70 fractionations were estimated by the intensity of bands of immunoblot and accounting for the protein volumes of the each fraction.

Adenovirus Construction. HA-epitope tagged full-length and deleted mutants *BRCA1* were inserted into AdEasy (Quantum Biotechnology, Inc.) shuttle vectors such that the *BRCA1* gene would be under the control of the cytomegalovirus promoter. Full-length HA-epitope tagged *BRCA1*, with the tag fused to the NH₂ terminus (HA-*BRCA1*) or to the COOH terminus (*BRCA1*-HA), were subcloned from constructs in the pcDNA3 vector (22). The 1-302 deletion was constructed by digestion of *HindIII* and *EcoRI* from *BRCA1*-HA and then ligated for insertion of the following forward (F) and reverse (R) linkers: F, 5'-AGCTTATAATGACCGGTG-3'; and R, 5'-AATTCACCGTCATTATA-3'. The 305-770 deletion was constructed by digestion of *EcoRI* and *KpnI* from HA-*BRCA1* and then ligated for insertion of the following forward (F) and reverse (R) linkers: F, 5'-AATTCGACCAAGAGAAGCGTAAGACCGGTCTGGTAC-3'; and R, 5'-CAGACCGGTCTTACGCTTCTTCTTGGTCCACCG-3'. The 775-1292 deletion has been described previously (25). The 1527-1863 deletion mutant was generated by digestion of full-length HA-*BRCA1* of pcDNA3-5' HA-*BRCA1* with *HindIII* and *SacI*, and then this fragment was inserted into the AdEasy shuttle vector. With each shuttle vector construct, recombination occurred in bacteria to recover adenoviral genomic DNA with the *BRCA1* gene, and virus was recovered following transfection into 293A cells. In two of the deletion mutants, $\Delta 305-770$ and $\Delta 775-1292$, the linker that replaced the *BRCA1* sequences also contained the nuclear localization sequence from the SV40 large T antigen, Pro-Lys-Lys-Lys-Arg-Lys.

Adenoviruses were prepared using standard protocols, and virus titers were determined by the TCID₅₀ method (Quantum Biotechnologies, Inc.). The MOI for each virus, when using 293 cells was: HA-*BRCA1* (full-length, NH₂-terminal tag), 0.8 pfu/cell; *BRCA1*-HA (full-length, COOH-terminal tag), 1.0

Received 12/14/01; accepted 5/22/02.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by Research Grant RPG-99-097-01 from the American Cancer Society, a grant from the Elsa U. Pardee Foundation (to J. D. P.), and Fellowship Grant DAMD17-00-0164 from the Department of Defense Breast Cancer Research Program (to N. C.).

² To whom requests for reprints should be addressed, at Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail: jparvin@rics.bwh.harvard.edu.

³ The abbreviations used are: holo-pol, polymerase II holoenzyme; Pol II, polymerase II; BARD1, *BRCA1*-associated RING domain protein; HUIC, hydroxyurea-induced complex; IP, immunoprecipitation; MOI, multiplicity of infection; pfu, plaque-forming unit.

pfu/cell; HA-BRCA1(Δ 1–302), 1.0 pfu/cell; HA-BRCA1(Δ 305–770), 0.6 pfu/cell; HA-BRCA1(Δ 775–1292), 0.4 pfu/cell; and HA-BRCA1(Δ 1527–1863), 0.6 pfu/cell. The MOI for each virus, when using MCF-10A cells was: HA-BRCA1 (full-length, amino-terminal tag), 120 pfu/cell; HA-BRCA1(Δ 1–302), 130 pfu/cell; HA-BRCA1(Δ 305–770), 50 pfu/cell; HA-BRCA1(Δ 775–1292), 80 pfu/cell; and HA-BRCA1(Δ 1527–1863), 80 pfu/cell. These MOIs were selected for equivalent levels of HA-tagged protein expression. With 293S cells infected at an MOI of $\sim$ 1, we estimated that $\sim$ 70% of the cells in the culture are infected. With MCF-10A cells infected at MOIs ranging from 50 to 130 pfu/cell, all cells in the culture were infected.

IP. One hundred fifty μ l of eluted protein from the Biorex70 column was immunoprecipitated with the specific antibody for human Med17 (26). Seven hundred fifty μ l of binding reactions were incubated with rotation for overnight at 4°C in buffer H [20 mM Tris-OAc (pH 7.9), 1 mM EDTA, and 5% glycerol, 0.12 M KOAc, 0.1% NP40, 0.1 mM DTT, 0.2 mg/ml BSA, and 0.5 mM phenylmethylsulfonyl fluoride] in the presence of protein extract, 5 μ l of antibody, and 20 μ l of protein A beads. These steps are performed with or without antigenic peptide (0.1 mg/ml). With all IPs, supernatant was removed, and protein beads were then washed three times using 800 μ l of wash buffer [120 mM KOAc, 20 mM Tris-OAc (pH 7.9), 0.1% NP40, 0.1 mM DTT, and 0.5 mM phenylmethylsulfonyl fluoride]. For Western blot analysis, samples were subjected to electrophoresis in 5% SDS-polyacrylamide gels and immunoblotted using the indicated antibodies.

Immunocytochemistry. 293A cells were grown in DMEM supplemented with 5% FBS, 100 μ g/ml penicillin and streptomycin, and infected with recombinant adenoviruses to express full-length HA-BRCA1, HA-BRCA1(Δ 1–302), HA-BRCA1(Δ 305–770), HA-BRCA1(Δ 775–1292), and HA-BRCA1(Δ 1527–1863). Cells were fixed for 10 min in PBS-buffered 3% paraformaldehyde and 2% sucrose solution, followed by 5-min permeabilization on ice in Triton buffer [0.5% Triton X-100 in 20 mM HEPES (pH 7.4), 50 mM NaCl, 3 mM MgCl₂, and 300 mM sucrose]. HA-BRCA1 was visualized with affinity-purified monoclonal antibody, HA.11 (Covance) as primary antibody, and FITC-conjugated secondary antibody. All images were collected by confocal microscopy.

RESULTS

Overexpression of BRCA1 Deletion Mutant Proteins. We have reported that BRCA1 could be resolved by our biochemical purification strategy into four distinct BRCA1-containing complexes: the holo-pol, a protein complex of unknown function we call the fraction 5 complex; the Rad50-Mre11-Nbs1 complex; and the HUIC (25). To characterize further the BRCA1 association with holo-pol, we prepared deletion mutants of BRCA1. The assay is to express the epitope-tagged BRCA1 deletion protein in large-scale culture and to purify the holo-pol and note the effect of the deletion. Four deletion mutants of epitope-tagged BRCA1, which nearly span the BRCA1 protein (Fig. 1A), were inserted into recombinant adenovirus and infected into 293S cells in suspension culture. One of these, the HA-BRCA1(Δ 775–1292) has been described previously (25). Infected whole cell extracts were prepared by standard procedures (2). Expression levels of full-length BRCA1 and the four deletions of HA-tagged BRCA1 in whole cell extracts were examined by immunoblot for the HA-epitope (Fig. 1B). As can be seen in Fig. 1B, the expression levels are approximately equal for each BRCA1 protein variant. Levels of tagged BRCA1 were $\sim$ 5-fold higher than endogenous BRCA1 in these extracts (data not shown). Important for analyzing protein complexes containing an overexpressed protein, cell localization data revealed no pool of cells with abnormally localized HA-BRCA1 (see Fig. 5). This suggests that protein purification data may reflect complexes with which BRCA1 is normally associated.

Whole cell extracts were chromatographed on Biorex70 ion exchange matrix, and protein fractions were eluted in washes of increasing concentration of potassium acetate (Fig. 2A) and analyzed by immunoblotting using antibody specific for the HA-tag and Pol II (Fig. 2B). The holo-pol complex and virtually all of the endogenous




Fig. 1. Deletion mutants of epitope-tagged BRCA1 overexpressed in large scale suspension culture. A, design of BRCA1 deletion mutants with locations of HA-tag and locations of nuclear localization signal (NLS). B, immunoblot of 270 μ g of whole cell extracts from: uninfected 293S cells (Lane 1, uninf.), full-length BRCA1 infected cells (Lane 2), and the indicated deletion mutant infected cells (Lanes 3–6). The blot was stained for HA-BRCA1.

BRCA1 fractionate in the 0.6 M step elution from this matrix. Unlike the tagged full-length BRCA1, the BRCA1 deletion mutants fractionated in multiple fractions from the Biorex70 matrix. Seventy % of the tagged full-length BRCA1 was fractionated in the 0.6 M KOAc fraction, and the 0.15 M KOAc flow through from this matrix contained $\sim$ 10% of the total tagged full-length BRCA1 protein (factoring in the large volume of the flow-through fraction). Fractionation results were similar for the BRCA1 containing the epitope tag fused to the COOH terminus (data not shown). On the other hand, 40–50% of HA-BRCA1(Δ 305–770) and HA-BRCA1(Δ 775–1292) were fractionated in the 0.6 M KOAc fraction and about 40–50% in the 0.15 M KOAc flow through. In the case of the COOH-terminal deletion mutant (Δ 1527–1863), 65% was eluted in the 0.15 M KOAc flow through and about 30% in the 0.6 M KOAc peak, lower than the other two internal deletion mutants. By contrast, 98% of the NH₂-terminal deletion mutant, BRCA1(Δ 1–302), was fractionated primarily in the 0.15 M KOAc flow through. In this sample, endogenous BRCA1 was mainly eluted in the 0.6 M KOAc fraction, as is normally observed (data not shown). Clearly, deletion of the BRCA1 NH₂ terminus reduced the association of BRCA1 with the holo-pol-containing fraction 50-fold. The COOH-terminal deletion resulted in a minor, $\sim$ 2-fold, decrease in association with the holo-pol-containing fraction.

Pol II had unchanged fractionation in these samples with the exception that expression of each BRCA1 deletion mutant resulted in some Pol II eluting in the flow-through fraction. Because it was possible that the small amount of Pol II eluting in the flow-through fraction was in fact holo-pol, we analyzed whether BRCA1 in the flow through was associated with holo-pol. This question was most critical for BRCA1(Δ 1–302), which had little fractionation in the 0.6 M salt elution, where the holo-pol is typically found. Using the holo-pol-specific, affinity-purified antibody against Med17 to immunopurify holo-pol from the flow-through fraction, we found that only a small amount of the Pol II in that fraction was associated with the holo-pol (Fig. 3A). By contrast, BRCA1(Δ 1–302), which primarily eluted in the flow through, had only background levels of binding to the holo-pol in that fraction (Fig. 3A). When this assay was repeated with other deletion mutants of BRCA1 in the flow-through fraction, the




Fig. 2. Fractionations of BRCA1 deletion mutants. **A**, scheme for the partial purification of holo-pol from adenovirus-infected cell extracts. **MW**, molecular weight. **B**, immunoblots of eluted fractions from Biorex70 matrix. Blots were stained for the HA epitope (left panel) and the Pol II large subunit (right panel). **C**, immunoblots of sucrose gradient sedimentation fractions. Blots were stained for the HA epitope (upper panel) and the Pol II large subunit (lower panel).

results were similar to as seen with Pol II. Only a small amount of protein in that fraction was associated with holo-pol (data not shown). These data are most consistent with the interpretation that overexpression of BRCA1 deletion mutants alters the holo-pol complex by causing more Pol II to fractionate in the flow-through fraction.

Interestingly, Western blots for Pol II in samples containing the COOH-terminal deletion mutant (Δ1527–1863) required prolonged exposure to visualize Pol II. We infer from the last observation that BRCA1 may be involved in the turnover of Pol II.

We next fractionated the 0.6 M KOAc fractions that contain holo-pol using sucrose gradient sedimentation and analyzed by immunoblotting using antibody specific for the HA-tag and Pol II (Fig. 2C). The full-length protein sediments in two protein peaks, the fraction 5 complex and the holo-pol, consistent with our prior observations (25). The fractionation patterns of HA-BRCA1(Δ305–770) and HA-BRCA1(Δ775–1292) were similar, and they made three peaks of HA-BRCA1. As we described in a previous report (25), these three peaks are the >60S fraction 5 complex, the 30S holo-pol complex, and the smaller HUIC. The COOH-terminal deletion mutant (Δ1527–1863) sedimented similarly as did the full-length HA-BRCA1 in only two complexes, the fraction 5 complex and the holo-pol. Because the

NH₂-terminal deletion mutant, HA-BRCA1(Δ1–302), was fractionated primarily in the 0.15 M KOAc flow through, we analyzed twice the amount of protein sample, and Western blots for HA-epitope required prolonged exposure to visualize HA-BRCA1. Although HA-BRCA1(Δ1–302) was fractionated broadly, it has three sedimentation peaks, consistent with a subset of this deletion mutant associated with the holo-pol. Clearly, most of the BRCA1(Δ1–302) protein does not cosediment with the holo-pol or the fraction 5 complex, although there is a minor peak of BRCA1(Δ1–302) that cosediments with the holo-pol in fractions 13–17. Recall that the vast majority of the expressed BRCA1(Δ1–302) did not copurify with the holo-pol on the first chromatographic step, making the results of the sedimentation profile suggest that only a little of this BRCA1 mutant associates with the holo-pol. BRCA1(Δ1–302) does cosediment in fractions 21–27, which contain the HUIC. Because we have identified BARD1 as a component of the HUIC, this is surprising for the BRCA1 mutant, which should not bind BARD1. The level of purification in fractions 21–27 was not high, indicating the likelihood that the cosedimentation of BRCA1(Δ1–302) with the HUIC was coincidental. Fractionation patterns of Pol II were consistent with previous observations of a broad peak typically centering on fraction 15. The pattern of the Pol II sedimentation was largely unchanged by the expression BRCA1 deletion mutants. The one exception was in the extract expressing




Fig. 3. Association of BRCA1 deletion mutants with the Pol II holoenzyme complex. **A**, IP by holo-pol-specific antibody directed against Med17, using 300 μl of 1.5 M KOAc Biorex70 flow through from HA-BRCA1(Δ1–302)-expressing cells as input. Ten % input protein is in the first lane, IP with Med17 in the presence of its antigenic peptide is in the second lane, and Med17 IP in the absence of blocking peptide is in the third lane. The top panel is stained using antibody specific for the HA epitope, and the bottom panel is stained using antibody specific for the large subunit of Pol II. **B**, IP by holo-pol-specific antibody directed against Med17, using 150 μl of 0.6 M KOAc Biorex70 eluate as inputs. All samples are evaluated in three: 10% input protein is in the first lane of each trio (Lanes 1, 4, 7, 11, and 14); IP with Med17 in the presence of its antigenic peptide is in the second lane of each set (Lanes 2, 5, 8, 12, and 15); and Med17 IP in the absence of blocking peptide is in the third lane of each set (Lanes 3, 6, 9, 13, and 16). The top panel is stained using antibody specific for the HA epitope. The second panel is stained using antibody specific for the BRCA1. The third panel is stained using antibody specific for the Pol II large subunit. The fourth panel is stained using antibody specific for the SWI/SNF subunit BRG1. The fifth panel is stained using antibody specific for the BRCA1-interactor, BARD1. All indicated bands migrated at positions consistent with their molecular weights.

HA-BRCA1(Δ 305–770); the peak of Pol II shifted slightly to a lower molecular weight, suggesting an alteration in the polymerase content in the holo-pol complex. These results suggest that, with the exception of HA-BRCA1(Δ 1–302), the deletion mutants of HA-BRCA1 copurify with holo-pol over two purification steps.

BARD1 Is a Component of holo-pol, and the NH₂-Terminal and the COOH-Terminal Regions of BRCA1 Are Both Important for Association with the holo-pol. Next, we tested whether these BRCA1 deletion mutants were truly associated with the holo-pol by IP using the holo-pol-specific antibody directed against Med17 (26). The antibody was affinity purified, and the input protein was the Biorex70 0.6 M KOAc eluate (Fig. 3B). All samples are evaluated in threes: 10% input protein was in the *first lane* of each trio (*Lanes 1, 4, 7, 11, and 14*), and IP with Med17 in the presence of its antigenic peptide was in the *second lane* of each set (*Lanes 2, 5, 8, 12, and 15*), and Med17 IP in the absence of blocking peptide in the *third lane* of each set (*Lanes 3, 6, 9, 13, and 16*). The use of the antigenic peptide in the *second lane* of each was to control for the specificity of the IP. Immunoblots were stained using antibodies specific for the HA epitope to detect overexpressed BRCA1 (*top*), endogenous BRCA1 (*second from top*), Pol II (*third panel*), SWI/SNF subunit BRG1 (*fourth panel*), and the BRCA1-interactor BARD1 (*bottom panel*). With the full-length HA-BRCA1 (*Lanes 1–3*), we observed HA-BRCA1, Pol II, BRG1, and BARD1, all associated with the Med17. The first three of these confirmed published results (1, 2), but the identification of BARD1 associated with the holo-pol has never been demonstrated. On Biorex70 column fractionation, the total cellular BARD1 separates into the flow through and 0.6 M eluates, and it was fractionated broadly in sucrose sedimentation, including holo-pol-containing fractions. Furthermore, these fractionation patterns of BARD1 did not change by overexpressing any of the BRCA1 full-length or deletion proteins (data not shown). These results suggest that, because BARD1 can be found in protein fractions that do not contain BRCA1, not all of the BARD1 in the cells is bound to BRCA1. Rad50, although present in the input sample, was negative for immunopurification by Med17 antibody (data not shown).

We next asked whether the BRCA1 deletion mutant proteins competed with endogenous BRCA1 for binding to the holo-pol. When analyzing the full-length HA-BRCA1, it comigrated with endogenous BRCA1, making it impossible to determine which BRCA1 protein was associated with the holo-pol. The deletion mutants HA-BRCA1(Δ 305–770) and HA-BRCA1(Δ 775–1292) were not different from the full-length BRCA1 with regard to association with Med17. Of interest in this analysis, because these mutants migrate faster than the endogenous BRCA1, we observed that these mutants competed with the endogenous BRCA1 for binding to the holo-pol (Fig. 3, *Lanes 4–9*). This result suggests that there exist in holo-pol complex a limited number of BRCA1 binding sites, and the overexpressed BRCA1 protein competed with the endogenous BRCA1 for binding. This competition for BRCA1 binding to the holo-pol attests to the specificity of the interaction between BRCA1 and the transcription complex.

The NH₂-terminal-deleted HA-BRCA1(Δ 1–302) was not enriched in the 0.6 M KOAc fraction (Fig. 2); thus, this mutant was not significantly present in the input. The small amount of HA-BRCA1(Δ 1–302) present in this sample does in fact appear to be associated with the holo-pol because a weak band was present in the IP (*Lane 13*). This residual binding is consistent with our prior observation that the COOH terminus of BRCA1 is important for binding the holo-pol (2). The very low amounts of HA-BRCA1(Δ 1–302) in the sample suggest, however, that there exist two domains of BRCA1 important for binding to the holo-pol, the NH₂ terminus and the COOH terminus. The NH₂ and COOH termini are partially re-

dundant for association with the holo-pol, but much less of the total cellular BRCA1(Δ 1–302) was in the holo-pol than was true for the other mutants. Endogenous BRCA1 was fractionated in the 0.6 M KOAc fraction and was not competed by low amount of HA-BRCA1(Δ 1–302) for binding the holo-pol (Fig. 3, *Lanes 11–13*). These BRCA1 purification and binding data, taken together with the presence of BARD1 in the holo-pol, suggest that both the BRCA1 NH₂ terminus and the COOH terminus are very important for association with the holo-pol.

The COOH-terminal-deleted HA-BRCA1 was associated with the Med17-containing holo-pol complex, and a low amount of endogenous BRCA1 was associated with the Med17 complex. By comparing the level of competition with endogenous BRCA1 for binding the holo-pol complex, the deletion mutants HA-BRCA1(Δ 305–770) and HA-BRCA1(Δ 775–1292) bound to the holo-pol with higher affinity than did the COOH-terminal-deleted BRCA1. This result suggests that the COOH-terminal deletion does in fact bind to the holo-pol, possibly because of the interaction of the NH₂ terminus of BRCA1 with the holo-pol, although the amount bound with holo-pol is reduced relative to the deletion mutants HA-BRCA1(Δ 305–770) and HA-BRCA1(Δ 775–1292) (Fig. 3, *Lanes 14–16*). Importantly, deletion of the NH₂ terminus of BRCA1 was found to have the most profound effect on associating with the holo-pol.

The NH₂-Terminus of BRCA1 Is Important for Formation of Nuclear Dots. Because BRCA1 has known to localize in nuclear dots in the S-phase of cell cycle (27), we tested which domain of BRCA1 affects this localization. 293A cells were infected with recombinant adenoviruses to express full-length HA-BRCA1 and each deletion variant (Fig. 4). Cells were stained with the anti-HA, monoclonal antibody HA.11, to visualize the expressed tagged HA-BRCA1 (Fig. 4, *A–E*) and stained with 4',6-diamidino-2-phenylindole to show the nucleus (Fig. 4, *F–J*). Expression of full-length HA-BRCA1, HA-BRCA1(Δ 305–770), HA-BRCA1(Δ 775–1292), and HA-BRCA1(Δ 1527–1863) and followed by probing cells using anti-HA antibody detected nuclear dots in ~10% cells. In all of these cases, we detected diffuse nuclear staining with 30–50 foci of recombinant BRCA1. Staining of cells expressing HA-BRCA1(Δ 1–302) revealed only homogenous nuclear staining without foci (Fig. 4B). The staining patterns were specific because immunofluorescence was negative when we used anti-HA antibody preincubated with its antigenic HA-peptide for 1 h on ice (data not shown). Staining by another monoclonal anti-HA antibody, 12CA5, and anti-BRCA1(Ab-1) yielded similar results. The Ab-1 antibody detected endogenous BRCA1 in nuclear foci, even in cells expressing HA-BRCA1(Δ 1–302), indicating that this mutant did not interfere with dot formation (data not shown). The results in Fig. 4 were typical for those seen on each monolayer, but accurate counts of stained cells were not possible using the 293 cells because these adhered poorly to the solid support. These results suggest that the NH₂ terminus of BRCA1, the deletion of which results in the most severe loss of interaction with holo-pol complex, is important in the formation of nuclear dots in S-phase.

Similar immunocytochemistry results were obtained using the mammary gland epithelial cell line, MCF-10A. We addressed whether there were any aberrant pools of overexpressed BRCA1 in the cells. One sign of an aberrant pool of BRCA1 would be identified by cytoplasmic accumulation. We found that the ectopically expressed HA-BRCA1 (full length) did have up to 20% of the cells with cytoplasmic staining (Fig. 5). Significantly, we observed that if the CRM1-dependent nuclear export was blocked by leptomycin B, then this protein was predominately nuclear. This suggests that the cytoplasmic BRCA1 in this experiment was not in fact aberrant, but it was regulated by the nuclear export machinery. Interestingly, the HA-BRCA1(Δ 1–302), which does not copurify with the holo-pol, was




Fig. 4. The NH₂ terminus of BRCA1 is important for nuclear dot formation. 293A cells were infected with recombinant adenovirus to express full-length HA-BRCA1 (A and F), HA-BRCA1(Δ1-302) (B and G), HA-BRCA1(Δ305-770) (C and H), HA-BRCA1(Δ775-1292) (D and I), and HA-BRCA1(Δ1527-1863) (E and J). Cells were fixed and stained with anti-HA antibody (A-E) and 4',6-diamidino-2-phenylindole (F-J), respectively.

exclusively nuclear, regardless of leptomycin B. This was likely attributable to deletion of the characterized nuclear export sequence in BRCA1 residues 89-100 (28). This result argues strongly that the failure of the BRCA1(Δ1-302) to associate with the holo-pol is not merely the result of abnormal shunting of the protein to the wrong cellular compartment but rather the deletion mutant is present in high concentration in the vicinity of the holo-pol. The other deletion mutants, which readily associate with the holo-pol, were observed to have the same subcellular distribution and response to leptomycin B, as did the full-length BRCA1 (Fig. 5A).

We determined the number of MCF-10A cells that form BRCA1 speckles when overexpressing tagged BRCA1 deletion proteins (Fig. 5B). We found that BRCA1-associated nuclear speckles were present in ~40% of the cells with nuclear staining when expressing full-length HA-BRCA1, BRCA1(Δ305-770), BRCA1(Δ775-1292), or BRCA1(Δ1527-1863) (Fig. 5B). The subcellular distribution and nuclear foci formation results were similar to those obtained in 293 cells, from which the protein preparations were derived, but in the latter case accurate cell counts were not possible because of the propensity of the cells to float.

DISCUSSION

Here we analyzed BRCA1 association with the holo-pol and the formation of nuclear foci by overexpressing deletion mutants of epitope-tagged BRCA1. These data showed that BARD1 is associated with the holo-pol complex and that the NH₂ terminus of BRCA1 is critical for BRCA1 association with holo-pol and for the formation of nuclear foci. The COOH terminus of BRCA1 also binds to the holo-pol, but it appears less significant than the NH₂-terminal domain.

BARD1 was found in multiple chromatographic fractions, even some fractions with undetectable BRCA1. BARD1 was associated with the holo-pol complex, BARD1 was purified by holo-pol-specific antibody, and this association was not affected by overexpression of deletion mutants of BRCA1.

The results from the various purification data are summarized in Fig. 6. The NH₂-terminal deletion mutant of BRCA1 interacts poorly with Med17-containing holo-pol complex. Instead, endogenous BRCA1 is interacting with holo-pol complex in this sample. This




Fig. 5. Subcellular localization of BRCA1 deletion mutants in the mammary epithelial cell line, MCF-10A. A, 2 days after infection of MCF-10A cells with the appropriate adenovirus-expressing BRCA1 variants, cells were analyzed by immunofluorescence. About 150 cells were analyzed for each condition, and the immunofluorescence was scored as nuclear (N), predominantly nuclear (N>C), equally distributed (N=C), and cytoplasmic (C). The nuclear export inhibitor, leptomycin B (LMB; 30 ng/ml), was added as indicated 8 h before staining. B, MCF-10A cells were treated as in A, without LMB, and in each sample 100 cells with predominantly nuclear staining of BRCA1 were counted for the presence of BRCA1-containing speckles.




Fig. 6. Model for interaction of BRCA1 deletion mutants with Med17 complex. See text for details. The deletions of BRCA1 residues 1–302 and 1527–1863 were abbreviated ΔN and ΔC , respectively.

deletion removes the characterized binding domains for BARD1, BAP1, and part of the domain for binding p53 (6, 16, 21). It was not determined which component of the holo-pol binds to the NH_2 terminus of BRCA1, although BARD1 is a good candidate because it is in the holo-pol and it binds to this domain of BRCA1. It was surprising that deletion of the NH_2 terminus of BRCA1 resulted in a >50-fold reduction in holo-pol association, whereas deletion of the BRCA1 COOH-terminal domain resulted in a 2-fold reduction in copurification with the holo-pol. Our published experiments have demonstrated that the COOH terminus of BRCA1 can bind to the holo-pol complex (1, 2). Both domains can independently bind to the holo-pol. Deletion of the BRCA1 COOH terminus does not abrogate interaction with the Med17-containing holo-pol complex, because the BRCA1 NH_2 terminus is still present in BRCA1($\Delta 1527$ –1863). Previous results in which deletion of the COOH-terminal 11 amino acids of BRCA1 resulted in diminished binding to the holo-pol (1), probably reflect a smaller fraction of the BRCA1 association with the holo-pol. Such a possibility is consistent with our observation of a quantitative decrease in HA-BRCA1($\Delta 1527$ –1863) copurifying with the holo-pol. Alternatively, the 11 amino acid truncation could cause misfolding and thus result in a more severe effect than the larger deletion. Previous analyses of the BRCA1 COOH terminus used *in vitro* binding assays, which reveal domains that function positively to bind. By contrast, in this study, we analyzed deletion mutants in the context of the rest of the BRCA1 and not a fusion protein. The results of this study revealed that although the COOH terminus could bind to the holo-pol, deletion of the NH_2 terminus had a more profound effect on holo-pol association.

Finally, we showed that the NH_2 terminus of BRCA1 is important for formation of nuclear foci. BRCA1 localizes to nuclear foci with BARD1 in S-phase (23, 24). This same NH_2 -terminal deletion, which no longer associates with nuclear foci, was at least 50-fold reduced for association with the holo-pol. It is possible that BRCA1 association with the holo-pol complex is important for formation of nuclear dots. Alternatively, the BRCA1 NH_2 terminus interacts with many proteins, and nuclear foci may result from one of these other interactions. We model that the holo-pol complex, containing BRCA1, functions in the surveillance of DNA for damage and upon encountering damaged DNA, ubiquitinates holo-pol components to recruit the proteasome, leading to a residual BRCA1-containing complex that binds to DNA

repair factors (29). This damage-surveillance model is consistent with our correlation that the NH_2 terminus of BRCA1 is important for both, binding to the holo-pol and binding with BRCA1 nuclear foci. Our prior observation that hydroxyurea treatment, which leads to halted DNA synthesis and DNA gaps, leads to a shift in BRCA1 content from the holo-pol to a new complex called the HUIC, which also contains BARD1 (25), is consistent with this concept of BRCA1 function. Perhaps the HUIC is the residual BRCA1-containing complex after the proteasome degrades many subunits of the holo-pol. Further work is aimed at testing this model for BRCA1 function and relating it to the etiology of breast cancer.

ACKNOWLEDGMENTS

We are grateful to R. Baer for providing antibody specific to BARD1.

REFERENCES

1. Scully, R., Anderson, S. F., Chao, D. M., Wei, W., Ye, L., Young, R. A., Livingston, D. M., and Parvin, J. D. BRCA1 is a component of the RNA polymerase II holoenzyme. *Proc. Natl. Acad. Sci. USA*, **94**: 5605–5610, 1997.
2. Neish, A. S., Anderson, S. F., Schlegel, B. P., Wei, W., and Parvin, J. D. Factors associated with the mammalian RNA polymerase II holoenzyme. *Nucleic Acids Res.*, **26**: 847–853, 1998.
3. Schlegel, B. P., Green, V. J., Ladias, J. A., and Parvin, J. D. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB1 α in activated transcription. *Proc. Natl. Acad. Sci. USA*, **97**: 3148–3153, 2000.
4. Haile, D. T., and Parvin, J. D. Activation of transcription *in vitro* by the BRCA1 carboxyl-terminal domain. *J. Biol. Chem.*, **274**: 2113–2137, 1999.
5. Anderson, S. F., Schlegel, B. P., Nakajima, T., Wolpin, E. S., and Parvin, J. D. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. *Nat. Genet.*, **19**: 254–256, 1998.
6. Zhang, H., Somasundaram, K., Peng, Y., Tian, H., Bi, D., Weber, B. L., and El-Deiry, W. S. BRCA1 physically associates with p53 and stimulates its transcriptional activity. *Oncogene*, **16**: 1713–1721, 1998.
7. Ouchi, T., Monteiro, A. N., August, A., Aaronson, S. A., and Hanafusa, H. BRCA1 regulates p53-dependent gene expression. *Proc. Natl. Acad. Sci. USA*, **95**: 2302–2306, 1998.
8. Ouchi, T., Lee, S. W., Ouchi, M., Aaronson, S. A., and Horvath, C. M. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN- γ target genes. *Proc. Natl. Acad. Sci. USA*, **97**: 5208–5213, 2000.
9. Wang, Q., Zhang, H., Kajino, K., and Greene, M. I. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells. *Oncogene*, **17**: 1939–1948, 1998.
10. Yu, X., Wu, L. C., Bowcock, A. M., Aronheim, A., and Baer, R. The C-terminal (BRCT) domains of BRCA1 interact *in vivo* with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. *J. Biol. Chem.*, **273**: 25388–25392, 1998.
11. Wong, A. K., Ormonde, P. A., Pero, R., Chen, Y., Lian, L., Salada, G., Berry, S., Lawrence, Q., Dayananth, P., Ha, P., Tavtigian, S. V., Teng, D. H., and Bartel, P. L. Characterization of a carboxy-terminal BRCA1 interacting protein. *Oncogene*, **17**: 2279–2285, 1998.
12. Zheng, L., Pan, H., Li, S., Flesken-Nikitin, A., Chen, P. L., Boyer, T. G., and Lee, W. H. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. *Mol. Cell*, **6**: 757–768, 2000.
13. Houvras, Y., Benezra, M., Zhang, H., Manfredi, J. J., Weber, B. L., and Licht, J. D. BRCA1 physically and functionally interacts with ATF1. *J. Biol. Chem.*, **275**: 36230–36237, 2000.
14. Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., Auborn, K. J., Goldberg, I. D., and Rosen, E. M. BRCA1 inhibition of estrogen receptor signaling in transfected cells. *Science (Wash. DC)*, **284**: 1354–1356, 1999.
15. Zheng, L., Annab, L. A., Afshari, C. A., Lee, W. H., and Boyer, T. G. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. *Proc. Natl. Acad. Sci. USA*, **98**: 9587–9592, 2001.
16. Wu, L. C., Wang, Z. W., Tsan, J. T., Spillman, M. A., Phung, A., Xu, X. L., Yang, M. C., Hwang, L. Y., Bowcock, A. M., and Baer, R. Identification of a RING protein that can interact *in vivo* with the BRCA1 gene product. *Nat. Genet.*, **14**: 430–440, 1996.
17. Kleiman, F. E., and Manley, J. L. The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression. *Cell*, **104**: 743–753, 2001.
18. Lorick, K. L., Jensen, J. P., Fang, S., Ong, A. M., Hatakeyama, S., and Weissman, A. M. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. *Proc. Natl. Acad. Sci. USA*, **96**: 11364–11369, 1999.
19. Ruffner, H., Joazeiro, C. A., Hemmati, D., Hunter, T., and Verma, I. M. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. *Proc. Natl. Acad. Sci. USA*, **98**: 5134–5139, 2001.

20. Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, H., and Ohta, T. The ring heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. *J. Biol. Chem.*, 276: 14537-14540, 2001.
21. Jensen, D. E., Proctor, M., Marquis, S. T., Gardner, H. P., Ha, S. I., Chodosh, L. A., Ishov, A. M., Tommerup, N., Vissing, H., Sekido, Y., Minna, J., Borodovsky, A., Schultz, D. C., Wilkinson, K. D., Maul, G. G., Barlev, N., Berger, S. L., Prendergast, G. C., and Rauscher, F. J., III. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. *Oncogene*, 16: 1097-1112, 1998.
22. Scully, R., Chen, J., Plug, A., Xiao, Y., Weaver, D., Feunteun, J., Ashley, T., and Livingston, D. M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. *Cell*, 88: 265-275, 1997.
23. Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., and Livingston, D. M. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. *Cell*, 90: 425-435, 1997.
24. Jin, Y., Xu, X. L., Yang, M. C., Wei, F., Ayi, T. C., Bowcock, A. M., and Baer, R. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. *Proc. Natl. Acad. Sci. USA*, 94: 12075-12080, 1997.
25. Chiba, N., and Parvin, J. D. Redistribution of BRCA1 among four different protein complexes following replication blockage. *J. Biol. Chem.*, 276: 38549-38554, 2001.
26. Chao, D. M., Gadbois, E. L., Murray, P. J., Anderson, S. F., Sonu, M. S., Parvin, J. D., and Young, R. A. A mammalian SRB protein associated with an RNA polymerase II holoenzyme. *Nature (Lond.)*, 380: 82-85, 1996.
27. Scully, R., Ganesan, S., Brown, M., De Caprio, J. A., Cannistra, S. A., Feunteun, J., Schnitt, S., and Livingston, D. M. Location of BRCA1 in human breast and ovarian cancer cells. *Science (Wash. DC)*, 272: 123-126, 1996.
28. Rodriguez, J. A., and Henderson, B. R. Identification of a functional nuclear export sequence in BRCA1. *J. Biol. Chem.*, 275: 38589-38596, 2000.
29. Parvin, J. D. BRCA1 at a branch point. *Proc. Natl. Acad. Sci. USA*, 98: 5952-5954, 2001.